Search Results 751-760 of 18279 for alopecia

1. Study of DF9001 in Patients With Advanced Solid Tumors - Mayo Clinic

   0; however, alopecia ≤Grade 2, endocrinopathies ≤Grade 2, and sensory neuropathy ≤Grade 2 is acceptable. 12. Participants who have received an anti-PD-(L ...

2. A Study to Analyze CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma - Mayo Clinic

   0], with the exception of persistent alopecia, hypothyroidism, and adrenal insufficiency) due to prior treatment. NOTE: Subjects previously treated with a ...

3. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

   Patient must be able to have recovered from all toxicities associated with chemoradiotherapy for anal cancer, to Grade ≤ 1 with the exception of alopecia.

4. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Patients with Solid Tumors - Mayo Clinic

   Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia). Known human immunodeficiency virus (HIV) ...

5. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

   Alopecia; Neuropathy resolved to ≤ Grade 2; Congestive heart failure that was ≤ Grade 1 in severity at the time of occurrence and resolved completely. Has ...

6. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

   Note: Stable chronic and clinically nonsignificant conditions (≤ Grade 2) that are not expected to resolve (eg, neuropathy, myalgia, alopecia, prior ...

7. Mayo Clinic

   Research & Education at Mayo Clinic. Research. Research at Mayo Clinic · Research Faculty · Laboratories · Core Facilities · Centers & Programs.

8. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma - Mayo Clinic

   Not recovered (i.e., to ≤ Grade 1 or to baseline) from AEs emerging from previous treatments (except alopecia or neuropathy). Incomplete recovery from AEs ...

9. A Study of Unesbulin Combined with Dacarbazine to Treat Advanced Leiomyosarcoma (LMS) - Mayo Clinic

   Toxicity from prior therapies recovered to Grade ≤ 1 or subject's baseline, except for alopecia. In addition, endocrinopathies associated with prior ...

10. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

    ... alopecia, vitiligo). Participants with Grade 2 toxicities that are deemed stable or irreversible (e.g., chemotherapy related arthritis or tendinitis, skin ...